Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silo Pharma Inc SILO

Healthcare Biotechnology
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and... see more

Recent & Breaking News (NDAQ:SILO)

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

GlobeNewswire February 18, 2021

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

GlobeNewswire February 10, 2021

Silo Pharma Inc. Engages CFN Enterprises Inc. to Reach Psychedelics Investor Audience

Newsfile February 10, 2021

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

GlobeNewswire January 26, 2021

Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast

Newsfile January 20, 2021

Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics

GlobeNewswire January 19, 2021

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

GlobeNewswire January 13, 2021

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

GlobeNewswire January 11, 2021

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

GlobeNewswire January 6, 2021

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

GlobeNewswire December 15, 2020

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

GlobeNewswire December 7, 2020

Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets

GlobeNewswire December 4, 2020

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide ("LSD") to Treat Parkinson's Disease

Business Wire December 2, 2020

Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco

GlobeNewswire November 16, 2020

Emerging Markets Report: Meeting the Moment

GlobeNewswire November 12, 2020

Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications

GlobeNewswire November 12, 2020

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University

GlobeNewswire November 9, 2020

Silo Pharma, Inc. (SILO) Announces Successful Uplisting To the OTCQB Venture Market

GlobeNewswire October 14, 2020

Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides

GlobeNewswire October 13, 2020

Silo Pharma, Inc. Expands Board with Appointment of Dr. Kevin Muñoz MD; Announces Application to Uplist to OTCQB Market

GlobeNewswire October 6, 2020